The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
ApexOnco Front Page
Recent articles
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
An actinium-based backup and Werner helicase inhibitor are notable absences.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
But the Astra/Daiichi ADC stumbles in lung cancer.
Cafelkibart’s entry into phase 3 is of note to Coherus.
